Acadia Pharmaceuticals

Valuation Analysis

About the Company

Acadia Pharmaceuticals en bref

Acadia Pharmaceuticals (ACAD) is currently trading at 18,87 € with a market capitalization of 3,2 Md €. The trailing P/E ratio stands at 9.78x, with a forward P/E of 24.21x. The 52-week range spans from 17,18 € to 24,74 €; the current price is 23.7% below the yearly high. Year-over-year revenue growth stands at +9.7%. The net profit margin stands at 34.3%.

💰 Dividende

Acadia Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

20 analystes évaluent Acadia Pharmaceuticals (ACAD) au consensus : None. L'objectif de cours moyen est de 27,62 €, soit un potentiel de +46.39% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 14,84 € à 39,27 €.

Acadia Pharmaceuticals : la thèse d'investissement en détail

Acadia Pharmaceuticals (ACAD) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 61.58%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 37.32% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 34.3%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Le scénario baissier

Short interest sits at 10.89% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

At a PEG of 50.86, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 30.04x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 46.39% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (10.89%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Acadia Pharmaceuticals?

Compare top-rated brokers — low fees, trusted providers, fully regulated.